{"id":17197,"date":"2023-07-25T09:44:36","date_gmt":"2023-07-25T13:44:36","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=17197"},"modified":"2025-02-15T17:45:18","modified_gmt":"2025-02-15T22:45:18","slug":"nord","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/it\/2023\/07\/25\/nord\/","title":{"rendered":"Il co-fondatore di PRF \u00e8 un leader di pensiero nello sviluppo di farmaci per le malattie rare"},"content":{"rendered":"<p>[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d0px||0px||\u201d locked=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_row _builder_version=\u201d4.16\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_image src=\u201dhttps:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/Lesliewcomputer.png\u201d title_text=\u201dLesliewcomputer\u201d _builder_version=\u201d4.21.0\u2033 _module_preset=\u201ddefault\u201d global_colors_info=\u201d{}\u201d][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.17.4\u2033 _module_preset=\u201ddefault\u201d custom_margin=\u201d||-77px|||\u201d global_colors_info=\u201d{}\u201d][et_pb_row _builder_version=\u201d4.17.4\u2033 _module_preset=\u201ddefault\u201d min_height=\u201d414.9px\u201d custom_margin=\u201d-88px|auto|-173px|auto||\u201d custom_padding=\u201d||45px|||\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.17.4\u2033 _module_preset=\u201ddefault\u201d global_colors_info=\u201d{}\u201d][et_pb_text _builder_version=\u201d4.21.0\u2033 _module_preset=\u201ddefault\u201d global_colors_info=\u201d{}\u201d]<\/p>\n<p>La co-fondatrice e direttrice medica della PRF, la dott.ssa Leslie Gordon, \u00e8 stata recentemente invitata a contribuire a una serie di video educativi prodotti dalla National Organization for Rare Disorders (NORD), insieme al suo collega dott. Francis Collins, consulente scientifico del Presidente degli Stati Uniti ed ex direttore dei National Institutes of Health (NIH).<\/p>\n<p>Ai due \u00e8 stato chiesto di condividere le lezioni apprese dalle loro esperienze nella ricerca sulla Progeria, a partire dallo sviluppo del Registro Internazionale della PRF nel 1999. Nei due video qui sotto, condividono le conclusioni sulla scoperta del gene della Progeria nel 2003, attraverso lo sviluppo del database medico e di ricerca della PRF, lo studio di storia naturale della PRF e infine attraverso l&#039;approvazione da parte della Food and Drug Administration (FDA) del lonafarnib, il primo trattamento in assoluto per la Progeria, per dimostrare possibili percorsi per far progredire la ricerca sulle malattie rare per coloro che sono coinvolti nella ricerca e nella difesa delle malattie rare.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=\u201dhttps:\/\/learn.rarediseases.org\/courses\/rare-disease-drug-development-series\/\u201d url_new_window=\u201don\u201d button_text=\u201d\u00c8 possibile accedere gratuitamente a questi video QUI nella serie sullo sviluppo di farmaci per le malattie rare di NORD.\u201d admin_label=\u201dDr. Leslie Gordon e Dr. Francis Collins\u201d _builder_version=\u201d4.22.1\u2033 _module_preset=\u201ddefault\u201d button_text_color=\u201d#FFFFFF\u201d button_bg_color=\u201d#29327A\u201d button_border_color=\u201d#8FD2ED\u201d background_layout=\u201ddark\u201d global_colors_info=\u201d{}\u201d][\/et_pb_button][et_pb_text _builder_version=\u201d4.22.1\u2033 _module_preset=\u201ddefault\u201d global_colors_info=\u201d{}\u201d]<\/p>\n<p><span>Questa serie completa \u00e8 estremamente informativa per chiunque sia interessato allo sviluppo di farmaci per le malattie rare; le interviste con il dott. Gordon e il dott. Collins si trovano nel modulo sugli studi di storia naturale di questa serie.<\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>Ascolta la co-fondatrice e direttrice medica del PRF, la dott.ssa Leslie Gordon, insieme al suo collega di lunga data, il dott. Francis Collins, condividere il loro percorso nello sviluppo di farmaci per le malattie rare per la serie educativa NORD. <\/p>","protected":false},"author":2,"featured_media":17213,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,1],"tags":[],"class_list":["post-17197","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>nord | The Progeria Research Foundation<\/title>\n<meta name=\"description\" content=\"Hear PRF co-founder and Medical Director, Dr. Leslie Gordon, along with long-time colleague Dr. Francis Collins, share their journey in rare disease drug development for NORD educational series.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/it\/2023\/07\/25\/nord\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"nord | The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"Hear PRF co-founder and Medical Director, Dr. Leslie Gordon, along with long-time colleague Dr. Francis Collins, share their journey in rare disease drug development for NORD educational series.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/it\/2023\/07\/25\/nord\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-25T13:44:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-15T22:45:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"PRF co-founder serves as thought leader in rare disease drug development\",\"datePublished\":\"2023-07-25T13:44:36+00:00\",\"dateModified\":\"2025-02-15T22:45:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/\"},\"wordCount\":435,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png\",\"articleSection\":[\"News\",\"Uncategorized\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/\",\"name\":\"nord | The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png\",\"datePublished\":\"2023-07-25T13:44:36+00:00\",\"dateModified\":\"2025-02-15T22:45:18+00:00\",\"description\":\"Hear PRF co-founder and Medical Director, Dr. Leslie Gordon, along with long-time colleague Dr. Francis Collins, share their journey in rare disease drug development for NORD educational series.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png\",\"width\":1000,\"height\":1000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRF co-founder serves as thought leader in rare disease drug development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/it\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"nord | La Fondazione per la Ricerca sulla Progeria","description":"Ascolta la co-fondatrice e direttrice medica del PRF, la dott.ssa Leslie Gordon, insieme al suo collega di lunga data, il dott. Francis Collins, condividere il loro percorso nello sviluppo di farmaci per le malattie rare per la serie educativa NORD.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/it\/2023\/07\/25\/nord\/","og_locale":"it_IT","og_type":"article","og_title":"nord | The Progeria Research Foundation","og_description":"Hear PRF co-founder and Medical Director, Dr. Leslie Gordon, along with long-time colleague Dr. Francis Collins, share their journey in rare disease drug development for NORD educational series.","og_url":"https:\/\/www.progeriaresearch.org\/it\/2023\/07\/25\/nord\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2023-07-25T13:44:36+00:00","article_modified_time":"2025-02-15T22:45:18+00:00","og_image":[{"width":1000,"height":1000,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png","type":"image\/png"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"2 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"PRF co-founder serves as thought leader in rare disease drug development","datePublished":"2023-07-25T13:44:36+00:00","dateModified":"2025-02-15T22:45:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/"},"wordCount":435,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png","articleSection":["News","Uncategorized"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/","url":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/","name":"nord | La Fondazione per la Ricerca sulla Progeria","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png","datePublished":"2023-07-25T13:44:36+00:00","dateModified":"2025-02-15T22:45:18+00:00","description":"Ascolta la co-fondatrice e direttrice medica del PRF, la dott.ssa Leslie Gordon, insieme al suo collega di lunga data, il dott. Francis Collins, condividere il loro percorso nello sviluppo di farmaci per le malattie rare per la serie educativa NORD.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2023\/07\/4LGFCNORD.png","width":1000,"height":1000},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/2023\/07\/25\/nord\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"PRF co-founder serves as thought leader in rare disease drug development"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"Fondazione per la ricerca sulla progeria","description":"Per i bambini \u2665 Per la cura","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"Fondazione per la ricerca sulla progeria","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"Karen Betournay","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/it\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/posts\/17197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/comments?post=17197"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/posts\/17197\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/media\/17213"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/media?parent=17197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/categories?post=17197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/it\/wp-json\/wp\/v2\/tags?post=17197"}],"curies":[{"name":"parola chiave","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}